Author:
Dakka Jumana,Turilli Matteo,Wright David W.,Zasada Stefan J.,Balasubramanian Vivek,Wan Shunzhou,Coveney Peter V.,Jha Shantenu
Publisher
Springer Science and Business Media LLC
Subject
Applied Mathematics,Computer Science Applications,Molecular Biology,Biochemistry,Structural Biology
Reference45 articles.
1. U. S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 2015. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm . Accessed 9 May 2015.
2. Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. Exploration of type ii binding mode: A privileged approach for kinase inhibitor focused drug discovery?. ACS Chem Biol. 2014; 9(6):1230–41.
3. American Cancer Society. Cancer Facts & Figures 2015. Am Cancer Soc. 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf . Accessed 7 May 2015.
4. Longley D, Johnston P. Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275–92.
5. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117–25.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献